Skip to content
← All interventions
Supplement

Alpha-ketoglutarate (AKG)

Evidence profile from the Longevity Compass research catalog.

Where the science stands

Detailed live evidence is temporarily unavailable in this preview. The intervention remains accessible while the live evidence connection is restored.

Evidence depth 57 / 100

Research path

From biological idea to human evidence

These stages show different kinds of evidence for Alpha-ketoglutarate (AKG). Moving through them does not mean an intervention is proven to slow aging.

  1. 1

    Biological idea

    Reviewing animal and laboratory research…

  2. 2

    Human testing

    0 human trial links tracked. A trial count describes research activity, not benefit.

  3. 3

    What results show

    Live result interpretation is temporarily unavailable.

  4. 4

    Still unanswered

    Detailed live evidence is temporarily unavailable in this preview. The intervention remains accessible while the live evidence connection is restored.

How AgeBeacon evaluates evidence →

Beyond human trials

The bigger longevity story

Loading animal and laboratory evidence…

Animal and cell studies help explain biological plausibility and identify promising directions. They are shown separately and do not increase the human evidence-depth score.

Research depth

Human evidence picture

Evidence depth describes how much relevant human research exists; it is not an efficacy score. Unknown results are not treated as neutral.

Live database metrics are not available; curated evidence is shown.

The big unanswered question

Can promising biology translate into meaningful healthy-aging benefits?

That is the standard this evidence profile is tracking. New trials and results can strengthen, weaken or change the picture over time.

Confidence: very-lowScore model: live-data-unavailableUpdated: 2026-09Source: curated fallback